Tseftobyprol

When ATH:
J01DI01

Pharmacological action.

Ceftobiprole of 16 % bound to plasma proteins, and the degree of bonding does not depend on its concentration. Bioprevrashtenie around prodrug Ceftobiprole medokarila the active drug - ceftobiprole is fast and is catalyzed by plasma esterases. The concentrations of prodrug are negligible, and it can be detected in plasma and urine only during infusion. Ceftobiprole undergoes minimal metabolism to non-cyclic metabolite, which is microbiologically inactive. The concentration of this metabolite concentrations below of ceftobiprole and is about 4 % from the last. Ceftobiprole is derived mainly unchanged through the renal excretion, T1 / 2 is about 3 no. The main mechanism of renal excretion is glomerular filtration, a small fraction of the dose undergoes tubular reabsorption. After the introduction of 1 dose of approximately 89 % it is found in the urine as active ceftobiprole (83 %), metabolite with an open ring (5 %) and ceftobiprole medokarila (< 1 %).

The pharmacokinetics of ceftobiprole is similar in healthy volunteers and in patients with mild renal insufficiency (Cl creatinine 50-80 ml / min).

Ceftobiprole undergoes minimal hepatic metabolism and is mainly excreted by the kidneys unchanged, and so there is no reason to believe, that the clearance of ceftobiprole in patients with hepatic impairment to be reduced.